Navigation Links
Shengtai Pharmaceutical Expands International Sales Program
Date:10/30/2008

- Dedicated Sales Team Focused on Key Global Markets -

WEIFANG, Shandong, China, Oct. 30 /Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it has restructured its international sales team committed to broaden Shengtai's product sales into selected global markets.

The international sales team is an integral part of our existing sales department as the Company sees growth potential in the overseas markets. Currently, the Company has existing customers in over 70 countries. The new team assumes responsibilities of all aspects of the international sales include research, regulatory affairs, marketing and sales to ensure the successful introduction of the Company's health and other products into targeted international markets. Shengtai's pharmaceutical grade glucose products have wide application in hospitals, clinics and other health-related services.

Recently, the international sales team attended the Guangzhou International Fair and presented Shengtai's products. The response from potential customers at this conference was encouraging.

Shengtai recently received the "Good Manufacturing Practice" (GMP) certificate for its new glucose manufacturing facility. This new facility has an annual production capacity of 120,000 tons and when combined with the existing plant provides the Company with a total annual capacity up to 180,000 tons of glucose. The Company is commencing operations in stages and will gradually ramp up production to expand its offerings.

Mr. Qingtai Liu, Chairman and CEO of Shengtai Pharmaceutical, stated, "Our high-quality products combined with low-cost, state-of-the-art manufacturing provides competitive advantages. We believe these advantages and our new production capacity will allow us to increase exports in targeted international markets."

"The Chinese market continues to represent a good growth opportunity for us as the economy is growing at approximately 8% in 2008. Additionally, the Chinese government is implementing policies to enhance economic growth through revised banking regulations to aid smaller businesses and effect reforms in rural areas to increase personal wealth, " Mr. Liu concluded.

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes, and the glucose and cornstarch products for the food and beverage industry and for industrial production in China. For more information about Shengtai Pharmaceutical, Inc., please visit http://www.shengtaipharmaceutical.com .

Safe Harbor Statement

Certain statements in this press release and oral statements made by the Company constitute forward-looking statements. These statements include, without limitation, statements regarding our ability to prepare the company for growth, the Company's planned capacity expansion in 2008 and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large scale implementation of the company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact:

Shengtai Pharmaceutical, Inc.

Ms. Yiru Melody Shi

Chief Financial Officer

Tel: +1-949-468-7078

Email: shengtaicfo@hotmail.com

Grayling Global

Eddie Cheung

Investor Relations

Tel: +1-646-284-9414

Email: echeung@hfgcg.com


'/>"/>
SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008
2. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
3. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
4. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
5. Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference
6. Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008
7. Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results
8. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
9. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
10. ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
11. ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: